Praxis Precision Medicines financials
$281.00−1.63%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $8.6M | $2.4M | $0.00 | — | — |
| Gross profit | $0.00 | $8.6M | $2.4M | $0.00 | — | — |
| Gross margin | — | 100.0% | 100.0% | — | — | — |
| Operating income | -$326.2M | -$200.2M | -$126.4M | -$215.0M | -$167.3M | -$62.0M |
| Net income | -$303.3M | -$182.8M | -$123.3M | -$214.0M | -$167.1M | -$70.3M |
| Net margin | — | −2137.5% | −5037.9% | — | — | — |
| Diluted EPS | $-13.48 | $-10.21 | $-18.69 | $-69.65 | $-59.10 | $-117.90 |
| EBITDA | -$326.1M | -$199.8M | -$125.9M | -$213.8M | -$167.2M | -$61.9M |
| Operating cash flow | -$249.1M | -$131.8M | -$111.1M | -$185.0M | -$124.6M | -$52.6M |
| Free cash flow | -$249.1M | -$131.8M | -$111.2M | -$185.5M | -$125.6M | -$52.6M |
| Diluted shares | 22.5M | 17.9M | 6.6M | 3.1M | 2.8M | 0.6M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $357.3M | $215.4M | $81.3M | $61.6M | $138.7M | $296.6M |
| Short-term investments | $242.0M | $177.2M | $0.00 | $38.9M | $137.2M | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $937.9M | $483.1M | $87.9M | $115.1M | $292.7M | $303.2M |
| Total liabilities | $59.8M | $37.7M | $18.3M | $39.0M | $41.9M | $15.7M |
| Shareholders' equity | $878.1M | $445.4M | $69.7M | $76.1M | $250.8M | $287.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology